Antoine Yrondi1,2,3, Djamila Bennabi1,4, Emmanuel Haffen1,5, Delphine Quelard6, Ludovic Samalin1,7, Julia Maruani1,8, Etienne Allauze1,7, Damien Pierre1,3, Thierry Bougerol1,9, Vincent Camus1,10, Thierry D'Amato1,11, Olivier Doumy1,12, Jérôme Holtzmann1,9, Christophe Lançon1,13, Fanny Moliere1,14, Rémi Moirand1,11, Isabel Nieto1,8, Raphaëlle Marie Richieri1,13, Mathilde Horn1,15, Laurent Schmitt1,3, Florian Stephan1,16, Jean-Baptiste Genty1,17, Guillaume Vaiva1,15, Michel Walter1,16, Philippe Courtet1,14, Marion Leboyer1,17, Pierre-Michel Llorca1,7, Sophie Marguet18, Nathalie Dennis18, Dominique Schaetz6, Wissam El-Hage1,10, Bruno Aouizerate1,12. 1. Fondation FondaMental, 94000 Créteil, France. 2. ToNIC Toulouse NeuroImaging Center, Université de Toulouse, INSERM, UPS, 31059 Toulouse, France. 3. Service de Psychiatrie et de Psychologie Médicale, Centre Expert Dépression Résistante FondaMental, 31059 Toulouse, France. 4. Service de Psychiatrie Clinique, Centre Expert Dépression Résistante FondaMental, EA 481 Neurosciences, Université de Bourgogne Franche Comté, 25000 Besançon, France. 5. Service de Psychiatrie Clinique, Centre Expert Dépression Résistante FondaMental, Centre Investigation Clinique 1431-INSERM, EA 481 Neurosciences, Université de Bourgogne Franche Comté, 25000 Besançon, France. 6. Janssen, 97132 Issy-Les-Moulineaux, France. 7. Service de Psychiatrie de L'adulte B, Centre Expert Dépression Résistante FondaMental, CHU de Clermont-Ferrand, 63000 Clermont-Ferrand, France. 8. Service de Psychiatrie Adulte, Centre Expert Dépression Résistante FondaMental, Hôpital Fernand-Widal, 75010 Paris, France. 9. Service de Psychiatrie de L'adulte, Centre Expert Dépression Résistante FondaMental, Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, 38000 Grenoble, France. 10. Clinique Psychiatrique Universitaire, Centre Expert Dépression Résistante FondaMental, Inserm U1253 Imaging and Brain, CHRU de Tours, 37000 Tours, France. 11. Service Universitaire de Psychiatrie Adulte, Centre Expert Dépression Résistante FondaMental, Centre Hospitalier Le Vinatier, 69500 Bron CEDEX, France. 12. Pôle de Psychiatrie Générale et Universitaire, Centre Expert Dépression Résistante FondaMental, CH Charles Perrens, NutriNeuro (UMR INRAE 1286), University of Bordeaux, 33000 Bordeaux, France. 13. Pôle Psychiatrie, Centre Expert Dépression Résistante FondaMental, CHU La Conception, 13000 Marseille, France. 14. Département des Urgences et Post-Urgences Psychiatriques, Centre Expert Dépression Résistante FondaMental, CHRU Lapeyronie, 34000 Montpellier, France. 15. Service de Psychiatrie Adulte, Centre Expert Dépression Résistante FondaMental, CHRU de Lille, Hôpital Fontan 1, 59000 Lille, France. 16. Service de Psychiatrie de L'adulte, Centre Expert Dépression Résistante FondaMental, CHU de Brest, Hôpital de Bohars, 29820 Bohars, France. 17. UPEC, AP-HP Département Hospitalo-Universitaire d'Addictologie et de Psychiatrie (DMU IMPACT) des Hôpitaux Universitaires Henri Mondor, Centre Expert Dépression Resistante de la Fondation FondaMental, 94000 Créteil, France. 18. Amaris, 75009 Paris, France.
Abstract
BACKGROUND: Major depressive disorder (MDD) is among the most common psychiatric disorders. One-third of patients are usually unresponsive to several lines of treatment. This study aimed to describe the FondaMental French cohort of patients with treatment-resistant depression (TRD) and to estimate utility and healthcare resource use outcomes. METHODS: Patients with TRD were evaluated prospectively over four years (baseline, 6, 12, 18, 24, 36 and 48 months) in a real-world clinical setting. Interim analyses focused on the first two consecutive years. Four MDD-related states (major depressive episode (MDE), response, remission, recovery) were defined based on the MADRS (Montgomery-Åsberg depression rating scale) and other clinical events. Health status was assessed with the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire. Utility values were estimated as preference measures that the patients assigned to their overall health status. RESULTS: This study was based on 252 patients with TRD. The mean utility value by health state was 0.41, 0.63, 0.80, and 0.90, for MDE, response, remission, and recovery, respectively. At baseline, 59% of patients had an MADRS score of at least 28. Their baseline average utility value was lower compared to the other patients (0.43 versus 0.58, p < 0.001). This significant difference persisted at the following visits. The rate of patients in MDEs having at least one hospitalisation for depression or other reasons than depression was generally higher than that in the other health states. CONCLUSION: This study documented patterns in healthcare resource consumption, quality of life, and other characteristics in patients with TRD, both globally and by health state and depression severity.
BACKGROUND: Major depressive disorder (MDD) is among the most common psychiatric disorders. One-third of patients are usually unresponsive to several lines of treatment. This study aimed to describe the FondaMental French cohort of patients with treatment-resistant depression (TRD) and to estimate utility and healthcare resource use outcomes. METHODS:Patients with TRD were evaluated prospectively over four years (baseline, 6, 12, 18, 24, 36 and 48 months) in a real-world clinical setting. Interim analyses focused on the first two consecutive years. Four MDD-related states (major depressive episode (MDE), response, remission, recovery) were defined based on the MADRS (Montgomery-Åsberg depression rating scale) and other clinical events. Health status was assessed with the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire. Utility values were estimated as preference measures that the patients assigned to their overall health status. RESULTS: This study was based on 252 patients with TRD. The mean utility value by health state was 0.41, 0.63, 0.80, and 0.90, for MDE, response, remission, and recovery, respectively. At baseline, 59% of patients had an MADRS score of at least 28. Their baseline average utility value was lower compared to the other patients (0.43 versus 0.58, p < 0.001). This significant difference persisted at the following visits. The rate of patients in MDEs having at least one hospitalisation for depression or other reasons than depression was generally higher than that in the other health states. CONCLUSION: This study documented patterns in healthcare resource consumption, quality of life, and other characteristics in patients with TRD, both globally and by health state and depression severity.
Authors: Scott T Aaronson; Peter Sears; Francis Ruvuna; Mark Bunker; Charles R Conway; Darin D Dougherty; Frederick W Reimherr; Thomas L Schwartz; John M Zajecka Journal: Am J Psychiatry Date: 2017-03-31 Impact factor: 18.112
Authors: Michael Charlton; Gregory T Everson; Steven L Flamm; Princy Kumar; Charles Landis; Robert S Brown; Michael W Fried; Norah A Terrault; Jacqueline G O'Leary; Hugo E Vargas; Alexander Kuo; Eugene Schiff; Mark S Sulkowski; Richard Gilroy; Kymberly D Watt; Kimberly Brown; Paul Kwo; Surakit Pungpapong; Kevin M Korenblat; Andrew J Muir; Lewis Teperman; Robert J Fontana; Jill Denning; Sarah Arterburn; Hadas Dvory-Sobol; Theo Brandt-Sarif; Phillip S Pang; John G McHutchison; K Rajender Reddy; Nezam Afdhal Journal: Gastroenterology Date: 2015-05-15 Impact factor: 22.682
Authors: Jasmina I Ivanova; Howard G Birnbaum; Yohanne Kidolezi; Ganesh Subramanian; Sajjad A Khan; Michael D Stensland Journal: Curr Med Res Opin Date: 2010-10 Impact factor: 2.580